Aldeyra Therapeutics (FRA:137) OCF Margin %: 0.00% (As of Mar. 2026)


FRA:137 Aldeyra Therapeutics Inc FRA:137
29 GF Score
Price €1.63
! 2 Warning Signs
View Full Analysis

What is Aldeyra Therapeutics OCF Margin %?

Aldeyra Therapeutics FRA:137 -7.91% 29 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:137 with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, Aldeyra Therapeutics ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Aldeyra Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was €-4.42 Mil. Aldeyra Therapeutics's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Aldeyra Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Aldeyra Therapeutics's current OCF Yield % is -22.67%.

The historical rank and industry rank for Aldeyra Therapeutics's OCF Margin % or its related term are showing as below:


FRA:137's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Aldeyra Therapeutics OCF Margin % Related Terms

Aldeyra Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Aldeyra Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aldeyra Therapeutics OCF Margin % Chart

Aldeyra Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aldeyra Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:137
29GF Score
Aldeyra Therapeutics Inc FRA:137
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aldeyra Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Aldeyra Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-28.477/0
= %

Aldeyra Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4.42/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Aldeyra Therapeutics (FRA:137) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Aldeyra Therapeutics and its competitors. According to the industry distribution chart, Aldeyra Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry.
Is Aldeyra Therapeutics' OCF Margin % too high?
Aldeyra Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Aldeyra Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aldeyra Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' OCF Margin % compare to CGTX and RANI?
According to the Biotechnology industry distribution chart, Aldeyra Therapeutics ranks #999999 out of 960 companies for OCF Margin %. This places Aldeyra Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Aldeyra Therapeutics and its competitors. Aldeyra Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (FRA:137) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Aldeyra Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Aldeyra Therapeutics (FRA:137), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aldeyra Therapeutics Business Description

Other Exchanges ALDX:USA137:Germany
Address 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score

Get the complete analysis for FRA:137

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.63
Price